OverviewSuggest Edit

Alimera Sciences is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is focused on diseases affecting the back of the eye, or retina. It provides ILUVIEN (fluocinolone acetonide intravitreal implant) for the treatment of diabetic macular edema (DME).
TypePublic
Founded2003
HQAlpharetta, GA, US
Websitealimerasciences.com
Employee Ratings3.8
Overall CultureB-

Latest Updates

Employees (est.) (Jan 2020)122(-1%)
Revenue (FY, 2019)$53.9 M(+15%)
Share Price (Jan 2021)$6 (+4%)
Cybersecurity ratingAMore

Key People/Management at Alimera Sciences

Ken Greene

Ken Greene

CSO
Rick Eiswirth

Rick Eiswirth

Director, President and Chief Executive Officer
Susan Caballa

Susan Caballa

Sr. Vice President, Regulatory & Medical Affairs
Brian Halak

Brian Halak

Director
Philip Ashman

Philip Ashman

Chief Operating Officer Senior Vice President, Commercial Operations Europe
Phil Jones

Phil Jones

Chief Financial Officer
Show more

Alimera Sciences Office Locations

Alimera Sciences has offices in Alpharetta, Berlin, Dublin 2, Lisboa and in 1 other location
Alpharetta, GA, US (HQ)
6120 Windward Pkwy #290
Berlin, DE
21 Cicerostraße
Dublin 2, IE
block c, Fitzwilliam Business Centre, 77 Sir John Rogerson's Quay, Dublin Docklands
Lisboa, PT
Avenida D. João II, 50 Edificio, R. do Mar Vermelho
Hampshire, GB
Wellesley Rd
Show all (5)

Alimera Sciences Financials and Metrics

Alimera Sciences Revenue

Alimera Sciences's revenue was reported to be $53.94 m in FY, 2019
USD

Revenue (Q3, 2020)

12.5m

Net income (Q3, 2020)

(618.0k)

EBIT (Q3, 2020)

407.0k

Market capitalization (13-Jan-2021)

33.5m

Closing stock price (13-Jan-2021)

6.0

Cash (30-Sept-2020)

11.3m

EV

66.4m
Alimera Sciences's current market capitalization is $33.5 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

1.9m8.4m22.4m34.3m35.9m47.0m53.9m

Revenue growth, %

350%166%53%

Cost of goods sold

1.9m1.4m1.8m2.3m3.4m4.7m

Gross profit

9.0k7.0m20.7m32.0m32.5m42.3m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

179.0k758.0k2.1m2.2m2.4m3.9m5.8m6.9m5.8m9.6m8.3m6.6m10.4m9.8m9.8m10.9m11.1m12.9m10.9m12.9m14.5m10.0m12.5m

Cost of goods sold

11.0k57.0k564.0k376.0k372.0k283.0k376.0k634.0k378.0k556.0k486.0k587.0k769.0k1.0m1.3m1.1m965.0k1.6m

Gross profit

168.0k701.0k1.5m1.8m2.0m3.7m5.4m6.3m5.4m9.0m7.8m6.0m9.6m8.7m8.5m9.8m10.2m11.3m

Gross profit Margin, %

94%92%73%83%85%93%93%91%93%94%94%91%93%89%87%90%91%88%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

33.1m49.6m12.6m76.7m31.1m31.0m24.1m13.0m9.4m

Accounts Receivable

500.0k850.0k9.8m13.8m11.4m17.3m19.3m

Prepaid Expenses

692.0k2.0m3.5m3.2m2.7m2.3m2.1m2.6m

Inventories

719.0k1.8m1.7m1.6m446.0k1.5m2.4m1.4m
USDQ2, 2011

Financial Leverage

1.3 x
Show all financial metrics

Alimera Sciences Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Alimera Sciences Online and Social Media Presence

Embed Graph

Alimera Sciences Company Culture

  • Overall Culture

    B-

    77/100

  • CEO Rating

    A+

    90/100

  • Compensation

    A

    88/100

Learn more on Comparably

Alimera Sciences News and Updates

Alimera Sciences to Present at the 13th Annual LD Micro Main Event Virtual Conference

ATLANTA, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that CEO Rick Eiswirth will present a corporate overview at…

Alimera Sciences Announces Participation at the 11th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 17, 2020

ATLANTA, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that Rick Eiswirth, Alimera’s President and Chief Executive…

Alimera Sciences Announces Real-World Clinical Data for ILUVIEN® to be Presented at the American Academy of Ophthalmology 2020 Virtual Conference

ATLANTA, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that new real-world clinical data for ILUVIEN® will be feat…

Alimera Sciences to Report Third Quarter 2020 Financial Results on Wednesday, October 28, 2020 and Provide Corporate Update

Conference Call to be held Thursday, October 29, 2020 at 9:00am Eastern Time Conference Call to be held Thursday, October 29, 2020 at 9:00am Eastern Time

Alimera Sciences Announces Multiple Posters and Papers Highlighting the Durability of ILUVIEN® To Be Presented at the EURETINA 2020 Virtual Congress

ATLANTA, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that clinical data for ILUVIEN® (fluocinolone acetonide intravit…

Alimera Sciences Announces National Reimbursement Granted for ILUVIEN® in the Netherlands

ILUVIEN receives pricing and reimbursement approvals for both diabetic macular edema and posterior uveitis indications simultaneously ILUVIEN receives pricing and reimbursement approvals for both diabetic macular edema and posterior uveitis indications simultaneously
Show more

Alimera Sciences Blogs

Alimera Sciences to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference

Alimera Sciences to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference

Alimera Sciences Announces Launch of ILUVIEN® in the Netherlands

Alimera Sciences Announces Launch of ILUVIEN® in the Netherlands

Alimera Sciences Announces Third Quarter 2020 Financial Results

Alimera Sciences Announces Third Quarter 2020 Financial Results

Alimera Sciences Reports Record Fourth Quarter and 2019 Results

Alimera Sciences Reports Record Fourth Quarter and 2019 Results Content Import Wed, 02/26/2020 - 16:07 Alimera Sciences Reports Record Fourth Quarter and 2019 Results Feb 26, 2020 This release is a backfill from a News Wire Earnings F…

Alimera Sciences Meets Revenue Milestone and Accesses Additional $2.5 Million Under Solar Debt Agreement

Alimera Sciences Meets Revenue Milestone and Accesses Additional $2.5 Million Under Solar Debt Agreement Content Import Mon, 02/24/2020 - 08:03 Alimera Sciences Meets Revenue Milestone and Accesses Additional $2.5 Million Under Solar Debt Agreement Feb 24, 2020 …

Alimera Sciences to Report Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26, 2020 and Provide Corporate Update

Alimera Sciences to Report Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26, 2020 and Provide Corporate Update Content Import Thu, 02/20/2020 - 08:01 Alimera Sciences to Report Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26, 2020 …
Show more

Alimera Sciences Frequently Asked Questions

  • When was Alimera Sciences founded?

    Alimera Sciences was founded in 2003.

  • Who are Alimera Sciences key executives?

    Alimera Sciences's key executives are Ken Greene, Rick Eiswirth and Susan Caballa.

  • How many employees does Alimera Sciences have?

    Alimera Sciences has 122 employees.

  • What is Alimera Sciences revenue?

    Latest Alimera Sciences annual revenue is $53.9 m.

  • What is Alimera Sciences revenue per employee?

    Latest Alimera Sciences revenue per employee is $442.2 k.

  • Who are Alimera Sciences competitors?

    Competitors of Alimera Sciences include BeyondSpring, Aimmune Therapeutics and Inovio Pharmaceuticals.

  • Where is Alimera Sciences headquarters?

    Alimera Sciences headquarters is located at 6120 Windward Pkwy #290, Alpharetta.

  • Where are Alimera Sciences offices?

    Alimera Sciences has offices in Alpharetta, Berlin, Dublin 2, Lisboa and in 1 other location.

  • How many offices does Alimera Sciences have?

    Alimera Sciences has 5 offices.